Quantel SA (Euronext: QUA), a leading manufacturer of solid state lasers, announced today that it has entered into a Distribution Agreement with National Biological, a leading researcher and developer of light-based systems for medical and cosmetic treatments, for Quantel's 308 Excimer System for monochromatic UVB treatment of psoriasis and vitiligo in the United States.
Monochromatic UVB Therapy
The 308 Excimer System was developed by Quantel Derma, GmbH based in Erlangen, Germany. Its monochromatic light is equivalent to an excimer laser, with comparable clinical results. The 308 Excimer System is portable, efficient and has no consumables.
National Biological's Chief Executive Officer, Ken Oif commented, "The Quantel 308 targeted phototherapy System provides the best solution for the tens of thousands of patients who require localized treatment for psoriasis, vitiligo, and other skin diseases which are responsive to UV light. It is proven to be very effective and extremely easy to use. National Biological is very pleased to be able to provide Dermatologists with the best value of any targeted phototherapy system."
Exclusivity in the United States
The 308 Excimer System will be exclusively marketed by National Biological in the United States. National Biological will provide the Marketing, Sales, Clinical and Service support.
Alain de Salaberry, Quantel's Président Directeur Général said: "Its strong sales organization and its experience with UVB devices make National Biological an ideal partner for the marketing of Quantel's 308 Excimer System."
New insights into the exacerbation of psoriasis through specific genetic defects